Understanding Clinical Hair Loss: Androgenetic Alopecia vs. Telogen Effluvium
Hair loss is a widespread medical concern that can deeply affect an individual’s psychological well-being. To address it effectively, dermatologists distinguish between different physiological forms of shedding. The two most common diagnoses are Androgenetic Alopecia (AGA) and Telogen Effluvium (TE). While both lead to visible hair thinning, their underlying cellular mechanisms, clinical progressions, and targeted treatment methodologies are fundamentally distinct.
Androgenetic Alopecia, commonly referred to as male or female pattern baldness, is a genetically predetermined, progressive condition. The driving force behind AGA is an increased sensitivity of hair follicles to male hormones, specifically Dihydrotestosterone (DHT). An enzyme called 5-alpha reductase converts systemically circulating testosterone into DHT within the scalp. Once bound to androgen receptors in genetically susceptible hair follicles, DHT alters the natural hair growth cycle. It shortens the active growing phase (anagen) and prolongs the resting phase (telogen). Over successive cycles, the hair follicles physically shrink in a biological process known as follicle miniaturization. As a result, terminal hairs—which are thick, pigmented, and robust—gradually transform into vellus hairs, which are fine, short, and barely visible. In men, this typically manifests as a receding hairline or thinning at the crown. In women, it presents as diffuse thinning across the top of the scalp with preservation of the frontal hairline.
In sharp contrast, Telogen Effluvium is a non-scarring, acute, or chronic form of diffuse hair shedding. Instead of being caused by progressive genetic sensitivity, TE is triggered by a significant physiological or psychological shock. Common triggers include high fevers, severe infections, childbirth, major surgeries, sudden nutritional deficiencies, or profound emotional stress. Under normal conditions, roughly 85% to 90% of scalp hair is actively growing in the anagen phase, while only 10% to 15% rests in the telogen phase. However, a major Hair Doctor in Kolkata systemic shock can prematurely shock up to 70% of active anagen hairs, forcing them directly into the resting telogen phase. Approximately two to three months after the triggering event, these shocked hairs begin to shed simultaneously. Unlike AGA, Telogen Effluvium does not cause follicle miniaturization. The hair follicles remain physically healthy and fully intact, meaning the shedding is usually temporary and reversible once the root cause is resolved.
Clinical management depends entirely on an accurate medical diagnosis. Because Androgenetic Alopecia is progressive, treatments focus on blocking DHT and revitalizing miniaturized follicles. Dermatologists frequently prescribe Finasteride, an oral 5-alpha reductase inhibitor that lowers systemic DHT levels, or topical Minoxidil, a powerful vasodilator that improves blood flow to malnourished follicles. For Telogen Effluvium, the primary clinical goal is identifying and correcting the underlying systemic trigger, such as resolving a vitamin deficiency or managing severe stress. For both conditions, advanced therapies like Platelet-Rich Plasma (PRP) can accelerate healing. PRP involves drawing a patient’s blood, spinning it to isolate growth-factor-rich platelets, and micro-injecting it into the scalp. These growth factors stimulate cell proliferation, prolong the anagen growth phase, and help restore the structural density of the hair.
